Cutler Group LP Calliditas Therapeutics Ab Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 18, 2024	BUY	$15.79 - $28.99 $1,579 - $2,899	100 New	100 $2,000
Q3 2022 Oct 25, 2022	SELL	$14.12 - $22.49 $4,800 - $7,646	-340 Reduced 60.71%	220 $3,000
Q2 2022 Aug 04, 2022	SELL	$12.85 - $20.36 $18,504 - $29,318	-1,440 Reduced 72.0%	560 $10,000
Q1 2022 Apr 14, 2022	BUY	$15.14 - $25.55 $24,678 - $41,646	1,630 Added 440.54%	2,000 $37,000
Q4 2021 Jan 18, 2022	BUY	$15.04 - $26.32 $5,564 - $9,738	370 New	370 $9,000

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.